KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Cash (2016 - 2025)

Historic Change in Cash for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$30.9 million.

  • Xenon Pharmaceuticals' Change in Cash rose 3715.11% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 24132.85%. This contributed to the annual value of -$5.9 million for FY2024, which is 10648.9% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Change in Cash of -$30.9 million as of Q3 2025, which was up 3715.11% from $18.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Change in Cash's 5-year high stood at $253.4 million during Q2 2022, with a 5-year trough of -$266.5 million in Q3 2022.
  • In the last 5 years, Xenon Pharmaceuticals' Change in Cash had a median value of $4.9 million in 2021 and averaged $3.1 million.
  • Examining YoY changes over the last 5 years, Xenon Pharmaceuticals' Change in Cash showed a top increase of 511376.85% in 2022 and a maximum decrease of 556214.39% in 2022.
  • Xenon Pharmaceuticals' Change in Cash (Quarter) stood at $87.9 million in 2021, then plummeted by 152.63% to -$46.2 million in 2022, then surged by 206.1% to $49.1 million in 2023, then grew by 12.27% to $55.1 million in 2024, then crashed by 156.03% to -$30.9 million in 2025.
  • Its Change in Cash stands at -$30.9 million for Q3 2025, versus $18.7 million for Q2 2025 and -$26.1 million for Q1 2025.